Get the Stockscreener App
0.9337
2.44%
-0.0234
Pre-market:
.93
-0.0037
-0.40%
Ovid Therapeutics Inc stock is traded at $0.9337, with a volume of 195.03K.
It is down -2.44% in the last 24 hours and down -18.10% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
See More
Previous Close:
$0.9571
Open:
$0.97
24h Volume:
195.03K
Relative Volume:
0.93
Market Cap:
$66.30M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-1.3339
EPS:
-0.7
Net Cash Flow:
$-45.92M
1W Performance:
-3.37%
1M Performance:
-18.10%
6M Performance:
+21.39%
1Y Performance:
-71.00%
1-Day Range:
$0.93
$0.9878
1-Week Range:
$0.93
$1.04
52-Week Range:
$0.68
$4.10
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
0.9337 | 66.30M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
402.70 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
712.33 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
615.00 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.31 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.95 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Ovid Therapeutics Inc (NASDAQ: OVID) Drops -2.44 Percent In Recent Trading, What Questions Do You Have? - Stocks Register
Ovid Therapeutics Inc. (NASDAQ:OVID) Sees Significant Growth in Short Interest - MarketBeat
Takeda Pharmaceutical & Ovid Therapeutics announces clinical development,commercialization collaboration for TAK-935 - Reuters
Fmr LLC Acquires 47,723 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Brokerages Set Ovid Therapeutics Inc. (NASDAQ:OVID) Price Target at $4.04 - Defense World
Analysts Set Ovid Therapeutics Inc. (NASDAQ:OVID) Price Target at $4.04 - MarketBeat
Verition Fund Management LLC Makes New Investment in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
BNP Paribas Financial Markets Boosts Stock Position in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
HC Wainwright Has Bullish Estimate for OVID FY2024 Earnings - MarketBeat
HC Wainwright Has Strong Forecast for OVID FY2024 Earnings - Defense World
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting - The Manila Times
Ovid Therapeutics to Present Multiple Posters Supporting - GlobeNewswire
Ovid Therapeutics Unveils Breakthrough Epilepsy Treatment Data at Major Conference | OVID Stock News - StockTitan
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus PT from Analysts - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Analysts - MarketBeat
B. Riley Decreases Earnings Estimates for Ovid Therapeutics - Defense World
Equities Analysts Offer Predictions for OVID FY2024 Earnings - MarketBeat
Fragile X Syndrome (Fxs) Treatment Market Growth Overview - openPR
Wedbush Forecasts Weaker Earnings for Ovid Therapeutics - Defense World
Equities Analysts Issue Forecasts for OVID FY2024 Earnings - Defense World
William Blair Has Positive Outlook for OVID FY2024 Earnings - MarketBeat
RFK Jr vow to purge FDA sets up collision with Big Pharma - Reuters
Ovid Therapeutics Inc (OVID) Quarterly 10-Q Report - Quartzy
William Blair Analysts Increase Earnings Estimates for OVID - MarketBeat
Ovid Therapeutics earnings beat, revenue topped estimates By Investing.com - Investing.com Canada
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results - GlobeNewswire
Ovid Therapeutics Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2024 - Marketscreener.com
US Penny Stocks To Watch This November 2024 - Simply Wall St
Ovid Therapeutics to Host Investor Event - GlobeNewswire
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Brokerages - MarketBeat
Layoff Tracker: Sage Therapeutics Will Lay Off 33% of Employees - BioSpace
Ovid Therapeutics (STU:1OT) Cyclically Adjusted Revenue per Share : €0.00 (As of Jun. 2024) - GuruFocus.com
Ovid Therapeutics (STU:1OT) Revenue per Share : €0.01 (TTM As of Jun. 2024) - GuruFocus.com
Patentability And Therapeutic Efficacy: Analysis Of Section 3(D) In Ovid Therapeutics v/s Controller Of Patents 2024 - Legal Service India
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
Marinus Pharmaceuticals' patent upheld by PTAB - Investing.com
Rhumbline Advisers Sells 12,851 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Patentability And Therapeutic Efficacy: Analysis Of Section 3(D) In Ovid Therapeutics v/s Controller Of Patents (2024) - Legal Service India
Ovid Therapeutics stock retains Buy rating from H.C. Wainwright By Investing.com - Investing.com Canada
Ovid Therapeutics stock retains Buy rating from H.C. Wainwright - Investing.com
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely? - Yahoo Finance
Ovid Therapeutics (NASDAQ:OVID) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Ovid Therapeutics (NASDAQ:OVID) - Defense World
1,400,191 Shares in Ovid Therapeutics Inc. (NASDAQ:OVID) Bought by Driehaus Capital Management LLC - MarketBeat
Ovid stock gets boost from promising OV329 toxicity profileB.Riley - Investing.com
Ovid reports promising safety profile for epilepsy drug OV329 - Investing.com
Ovid Therapeutics Presents Pre-Clinical Study Results - GlobeNewswire
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin - StockTitan
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):